A5065549220- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Single-cell and spatial transcriptomics
- CNS Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- Cancer Genomics and Diagnostics
- T-cell and B-cell Immunology
- Eosinophilic Disorders and Syndromes
- Polyomavirus and related diseases
- Cancer Immunotherapy and Biomarkers
- Prostate Cancer Treatment and Research
- Viral Infectious Diseases and Gene Expression in Insects
- Acute Lymphoblastic Leukemia research
- Genetic factors in colorectal cancer
- Mast cells and histamine
- Medical Imaging Techniques and Applications
- Ubiquitin and proteasome pathways
- Radiomics and Machine Learning in Medical Imaging
- Immunodeficiency and Autoimmune Disorders
- Immunotherapy and Immune Responses
- Cutaneous lymphoproliferative disorders research
Uppsala University
2016-2025
Uppsala University Hospital
2016-2025
Science for Life Laboratory
2015-2023
King's College London
2016
Kings Health Partners
2016
University College London
2016
London Cancer
2016
Cancer Research UK
2016
St Thomas' Hospital
2016
Auckland City Hospital
2016
We tested interim positron-emission tomography–computed tomography (PET-CT) as a measure of early response to chemotherapy in order guide treatment for patients with advanced Hodgkin’s lymphoma.
Abstract Purpose: The chimeric antigen receptor (CAR) T-cell therapy has been effective for patients with CD19+ B-cell malignancies. Most studies have investigated the second-generation CARs either CD28 or 4-1BB costimulatory domains in CAR receptor. Here, we describe first clinical phase I/IIa trial using third-generation T cells targeting CD19 to evaluate safety and efficacy. Patients Methods: Fifteen lymphoma leukemia were treated cells. received chemotherapy during manufacture 11 of 15...
Summary. Hodgkin's lymphoma (HL) is characterized by a few Hodgkin, Reed–Sternberg cells (HRS) surrounded benign cells. We recently reported that mast were the predominant CD30L‐positive in HL tumours, and they activate HRS vitro through CD30L–CD30 interaction. Here, we investigated clinical importance of cell infiltration tumours 123 patients. Tumour specimens stained with mast‐cell‐specific antibody detects tryptase. Mast detected virtually every case increasing numbers correlated to...
Purpose The aim was to investigate male and female cancer survivors' perception of fertility-related information use fertility preservation (FP) in connection with treatment during reproductive age. Methods study sample consisted survivors diagnosed from 2003 2007 identified population-based registers Sweden. Inclusion criteria included who were age 18 45 years at diagnosis had lymphoma, acute leukemia, testicular cancer, ovarian or breast treated chemotherapy. Of 810 eligible participants,...
NF-κB is constitutively activated in chronic lymphocytic leukemia (CLL); however, the implicated molecular mechanisms remain largely unknown. Thus, we performed targeted deep sequencing of 18 core complex genes within pathway a discovery and validation CLL cohort totaling 315 cases. The most frequently mutated gene was NFKBIE (21/315 cases; 7%), which encodes IκBε, negative regulator normal B cells. Strikingly, 13 these cases carried an identical 4-bp frameshift deletion, resulting truncated...
Cancer mortality is exacerbated by late-stage diagnosis. Liquid biopsies based on genomic biomarkers can noninvasively diagnose cancers. However, validation studies have reported ~10% sensitivity to detect stage I cancer in a screening population and specific types, such as brain or genitourinary tumors, remain undetectable. We investigated urine plasma free glycosaminoglycan profiles (GAGomes) tumor metabolism for multi-cancer early detection (MCED) of 14 types using 2,064 samples from...
Here, we report the first comparative analysis of patient-reported outcomes (PROs) with chimeric antigen receptor T-cell therapy vs standard-of-care (SOC) in second-line relapsed/refractory large B-cell lymphoma (R/R LBCL) from pivotal randomized phase 3 ZUMA-7 study axicabtagene ciloleucel (axi-cel) SOC. PRO instruments were administered at baseline, day 50, 100, 150, month 9, and every months randomization until 24 or an event-free survival event. The quality life (QoL) set comprised...
Abstract A comprehensive characterization of blood proteome profiles in cancer patients can contribute to a better understanding the disease etiology, resulting earlier diagnosis, risk stratification and monitoring different subtypes. Here, we describe use next generation protein profiling explore signature across representing many major types. Plasma 1463 proteins from more than 1400 are measured minute amounts collected at time diagnosis before treatment. An open access Disease Blood Atlas...
Recent transcriptomic-based analysis of diffuse large B cell lymphoma (DLBCL) has highlighted the clinical relevance lymph node (LN) fibroblast and tumor-infiltrating lymphocyte (TIL) signatures within tumor microenvironment (TME). However, immunomodulatory role fibroblasts in remains unclear. Here, by studying human mouse DLBCL-LNs, we identify presence an aberrantly remodeled fibroblastic reticular (FRC) network, expressing elevated activated protein (FAP). RNA-sequencing analyses reveal...
Mast cells are involved in many disorders where the triggering mechanism that leads to degranulation and/or cytokine secretion has not been defined. Several chronic inflammatory diseases associated with increased mast cell numbers and upregulation of TNF receptor family member CD30, but role elevated CD30 expression is poorly understood. Here we report what believe be a novel way activate degranulation-independent chemokines. induced de novo synthesis chemokines IL-8, macrophage...
HL is a malignant lymphoma characterized by small number of HRS cells among major population infiltrating reactive cells, e.g., lymphocytes and eosinophils. We previously reported that mast are present in HL-affected lymph nodes therein the predominant CD30L-expressing cells. The CD30L expressed on functionally active can provide stimulatory signals to Thus, constitute an important portion contribute tumor progression HL. Control recruitment this unrecognized cell its interactions with...
DNA repair mechanisms are fundamental for B cell development, which relies on the somatic diversification of immunoglobulin genes by V(D)J recombination, hypermutation, and class switch recombination. Their failure is postulated to promote genomic instability malignant transformation in cells. By performing targeted sequencing 73 key 29 lymphoma samples, germline mutations were identified various pathways, mainly diffuse large lymphomas (DLBCLs). Mutations mismatch (EXO1, MSH2, MSH6)...
Epstein-Barr virus (EBV) plays a major role in the development of post-transplant lymphoproliferative disorder (PTLD), but there is an increasing awareness EBV-negative PTLD. The clinical presentation PTLD has not been as well characterised EBV-positive cases. Further, limited knowledge on importance diffuse large B-cell lymphoma (DLBCL) cell origin subtype post-transplant.We studied EBV, hepatitis C (HCV) and DLBCL survival 135 lymphomas diagnosed 1980-2006 population-based cohort 10 010...
Progress in cancer biomarker discovery is dependent on access to high-quality biological materials and high-resolution clinical data from the same cases. To overcome current limitations, a systematic prospective longitudinal sampling of multidisciplinary data, blood tissue patients was therefore initiated 2010 by Uppsala Umeå Universities involving their corresponding University Hospitals, which are referral centers for one third Swedish population.Patients with selected types who treated at...
Abstract We performed a national population-based study of all patients diagnosed with diffuse large B-cell lymphoma (DLBCL) in Sweden 2007–2014 to assess treatment intent and risk relapsed/refractory disease, including central nervous system (CNS) relapse, the presence competing risks. Overall, 84% started curative (anthracycline-based) ( n = 3550, median age 69 years), whereas 14% did not 594, 84 years) (for 2% was uncertain). Patients treated had 5-year OS 65.3% (95% CI: 63.7–66.9). The...